BMS-984923 for Parkinson's Disease
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stay on your current Parkinson's disease medications and any other stable non-Parkinson's medications for at least 28 days before starting and throughout the study. However, you cannot take medications that might interact with the study drug during the trial.
What data supports the effectiveness of the drug BMS-9894923, ALX-001 for Parkinson's Disease?
The research highlights the potential of targeting metabotropic glutamate receptors, like mGluR4, for treating Parkinson's disease symptoms. Similar treatments, such as TAS-4, have shown promise in animal models by improving movement issues without worsening side effects, suggesting that BMS-9894923, ALX-001 might also be effective.12345
How is the drug BMS-984923 different from other Parkinson's disease treatments?
BMS-984923 (also known as ALX-001) is unique because it may target specific receptors or pathways not addressed by current Parkinson's treatments, potentially offering a new approach to managing symptoms or side effects like dyskinesia (involuntary movements) associated with long-term use of existing medications like L-DOPA.46789
What is the purpose of this trial?
A Phase 1, randomized, double-blind, placebo-controlled study of BMS-984923 administered orally twice daily (BID) for 28 days in participants with Parkinson's disease.
Research Team
Laurie Sanders, Ph.D
Principal Investigator
Duke University
Eligibility Criteria
Adults aged 50-80 with Parkinson's disease, able to follow the study plan and on stable PD therapy. They must not have severe symptoms, cognitive impairment, or a history of certain medical conditions. Participants need to use effective contraception if they can have children.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-984923 or placebo orally twice daily for 28 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BMS-9894923
Find a Clinic Near You
Who Is Running the Clinical Trial?
Allyx Therapeutics
Lead Sponsor
Michael J. Fox Foundation for Parkinson's Research
Collaborator